《股市简讯》中国恒瑞医药涨2%，药物纳入拟突破性治疗品种公示名单

路透中文12-17 11:18

《股市简讯》中国<a href="https://laohu8.com/S/600276">恒瑞医药</a>涨2%，药物纳入拟突破性治疗品种公示名单

* 中国恒瑞医药600276.SS周二早盘涨2%。

* 公司公告称，子公司苏州盛迪亚生物医药有限公司的注射用瑞康曲妥珠单抗（SHR-A1811）被国家药品监督管理局药品审评中心纳入拟突破性治疗品种公示名单。

拟定适应症为用于治疗人表皮生长因子受体2（HER2）表达的铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌。（完）

更多股市简讯请点选CN-CMN-HOT

(发稿刘珞焱；审校林高丽)

((luoyan.liu@tr.com; +86 021 2083 0166;))

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492711603?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-17 11:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492711603","market":"us","top_or_hot":-1,"title":"《股市简讯》中国恒瑞医药涨2%，药物纳入拟突破性治疗品种公示名单","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》中国<a href=\"https://laohu8.com/S/600276\">恒瑞医药</a>涨2%，药物纳入拟突破性治疗品种公示名单</title></head><body><p>* 中国恒瑞医药<span>600276.SS</span>周二早盘涨2%。</p><p>* 公司<span>公告</span>称，子公司苏州盛迪亚生物医药有限公司的注射用瑞康曲妥珠单抗（SHR-A1811）被国家药品监督管理局药品审评中心纳入拟突破性治疗品种公示名单。</p><p>拟定适应症为用于治疗人表皮生长因子受体2（HER2）表达的铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌。（完） </p><p>更多股市简讯请点选<span>CN-CMN-HOT</span></p><p> (发稿 刘珞焱；审校 林高丽)</p><p> ((luoyan.liu@tr.com; +86 021 2083 0166;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市简讯》中国恒瑞医药涨2%，药物纳入拟突破性治疗品种公示名单</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市简讯》中国恒瑞医药涨2%，药物纳入拟突破性治疗品种公示名单\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 11:18 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4T3NI073:1><strong>路透中文</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>《股市简讯》中国恒瑞医药涨2%，药物纳入拟突破性治疗品种公示名单* 中国恒瑞医药600276.SS周二早盘涨2%。* 公司公告称，子公司苏州盛迪亚生物医药有限公司的注射用瑞康曲妥珠单抗（SHR-A1811）被国家药品监督管理局药品审评中心纳入拟突破性治疗品种公示名单。拟定适应症为用于治疗人表皮生长因子受体2（HER2）表达的铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌。（完） 更多股市简讯请点选...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4T3NI073:1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1064131003.USD","symbol_name":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4T3NI073:1","article_id":"2492711603","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492711603","pubTimestamp":1734405486,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市简讯》中国恒瑞医药涨2%，药物纳入拟突破性治疗品种公示名单* 中国恒瑞医药600276.SS周二早盘涨2%。* 公司公告称，子公司苏州盛迪亚生物医药有限公司的注射用瑞康曲妥珠单抗（SHR-A1811）被国家药品监督管理局药品审评中心纳入拟突破性治疗品种公示名单。拟定适应症为用于治疗人表皮生长因子受体2（HER2）表达的铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌。（完） 更多股市简讯请点选CN-CMN-HOT (发稿 刘珞焱；审校 林高丽) ((luoyan.liu@tr.com; +86 021 2083 0166;))","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0188":"融资融券","BK0028":"国家队","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0060":"抗癌","BK0183":"MSCI概念","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0239":"医药制造","BK0012":"证金概念","BK0196":"行业龙头"},"translate_title":"\"Stock Market Newsletter\" China Hengrui Medicine rose 2%, and the drug was included in the announcement list of proposed breakthrough therapeutic products","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9},"content_text":"《股市简讯》中国恒瑞医药涨2%，药物纳入拟突破性治疗品种公示名单* 中国恒瑞医药600276.SS周二早盘涨2%。* 公司公告称，子公司苏州盛迪亚生物医药有限公司的注射用瑞康曲妥珠单抗（SHR-A1811）被国家药品监督管理局药品审评中心纳入拟突破性治疗品种公示名单。拟定适应症为用于治疗人表皮生长因子受体2（HER2）表达的铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌。（完） 更多股市简讯请点选CN-CMN-HOT (发稿 刘珞焱；审校 林高丽) ((luoyan.liu@tr.com; +86 021 2083 0166;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492711603"}